63897-12-1

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE is used as a chemical intermediate for the synthesis of pharmaceutical compounds, particularly those with antimicrobial or antifungal properties. Its unique structure contributes to the development of new drugs with enhanced therapeutic effects.
Used in Agrochemical Industry:
2,4-DICHLORO-6-METHYL-3-NITROPYRIDINE is used as a building block in the production of herbicides and insecticides. Its incorporation into these agrochemicals aids in the control of pests and weeds, thereby improving crop yields and quality.

InChI:InChI=1/C6H4Cl2N2O2/c1-3-2-4(7)5(10(11)12)6(8)9-3/h2H,1H3

Upstream product

• 4966-90-9 2,4-Dihydroxy-6-methyl-3-nitropyridine 
• 675-10-5 4-hydroxy-6-methyl-2-pyron 
• 4966-90-9 4-hydroxy-6-methyl-3-nitro-2(1H)-pyridinone 
• 10025-87-3 trichlorophosphate 
• 3749-51-7 4-hydroxy-6-methyl-2-pyridone 

Downstream Products

• 179056-98-5 3-amino-2,4-dichloro-6-methylpyridine 
• 220953-56-0 3-amino-2--4-(N-butyl-N-ethylamino)-6-methylpyridine 
• 220953-62-8 butyl-ethyl-[3-(4-isopropyl-2-methylsulfanyl-phenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine 
• 220953-58-2 3-amino-2--4-(N-butyl-N-ethylamino)-6-methylpyridine 
• 220953-53-7 N²-(2-bromo-4-isopropylphenyl)-N⁴-butyl-N⁴-ethyl-6-methyl-3-nitropyridine-2,4-diamine 
• 220953-64-0 [3-(4-isopropyl-2-methylsulfanyl-phenyl)-5-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-bis-(2-methoxy-ethyl)-amine 
• 220953-59-3 3-amino-2--4--6-methylpyridine 
• 220953-57-1 3-amino-2--4-(N,N-bis(methoxyethyl)amino)-6-methylpyridine 
• 220953-55-9 2--4-(N-butyl-N-ethylamino)-6-methyl-3-nitropyridine 
• 220953-54-8 2--4-(N,N-bis(methoxyethyl)amino)-6-methyl-3-nitropyridine 

Relevant academic research and scientific papers

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and

Substituted benzimidazoles as modulators of Ras signaling

Benzimidazole compounds that increase the rate of SOS-mediated nucleotide exchange on Ras by binding to a functionally relevant, chemically tractable pocket on the SOS protein, as part of the Ras:SOS:Ras complex.

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.

Discovery of imigliptin, a novel selective DPP-4 inhibitor for the treatment of type 2 diabetes

We report our discovery of a novel series of potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Starting from a lead identified by scaffold-hopping approach, our discovery and development efforts were focused on exploring structure-activity relationships, optimizing pharmacokinetic profile, improving in vitro and in vivo efficacy, and evaluating safety profile. The selected candidate, Imigliptin, is now undergoing clinical trial.

FUSED PYRIDINE DERIVATIVES

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.

FUSED PYRIDINE DERIVATIVES

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.

1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula (I) or a salt thereof are provided, wherein X1, X2, X3, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating

Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: Mapping of the receptor binding pocket by in silico docking studies

In an effort to discover novel CRF-1 receptor antagonists exhibiting improved physicochemical properties, a dihydropirrole[2,3]pyridine scaffold was designed and explored in terms of the SAR of the substitution at the pendent phenyl ring and the nature of

2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization

Two types of adenosine receptor ligands were designed, i.e., 9H-purine and 1H-imidazo[4,5-c]pyridines, to obtain selective A2A antagonists, and we report here their synthesis and binding affinities for the four adenosine receptor subtypes Asub

Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists

The synthesis and SAR studies of tricyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF1) antagonists are discussed herein. Compound 16g was identified as a functional antagonist that inhibited CRF-stimulat